Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study von Keystone, E C, Genovese, M C, Klareskog, L, Hsia, E C, Hall, S T, Miranda, P C, Pazdur, J, Bae, S-C, Palmer, W, Zrubek, J, Wiekowski, M, Visvanathan, S, Wu, Z, Rahman, M U

Volltext

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events von Leombruno, J P, Einarson, T R, Keystone, E C

Volltext

Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients von Curtis, J. R., Yang, S., Chen, L., Pope, J. E., Keystone, E. C., Haraoui, B., Boire, G., Thorne, J. C., Tin, D., Hitchon, C. A., Bingham, C. O., Bykerk, V. P.

Volltext

Consensus statement on the use of rituximab in patients with rheumatoid arthritis von Smolen, J S, Keystone, E C, Emery, P, Breedveld, F C, Betteridge, N, Burmester, G R, Dougados, M, Ferraccioli, G, Jaeger, U, Klareskog, L, Kvien, T K, Martin-Mola, E, Pavelka, K

Volltext

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study von Weinblatt, M E, Keystone, E C, Furst, D E, Kavanaugh, A F, Chartash, E K, Segurado, O G

Volltext

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of... von Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, J W J, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J

Volltext

Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remissio... von Kuriya, B, Arkema, E V, Bykerk, V P, Keystone, E C

Volltext

The utility of tumour necrosis factor blockade in orphan diseases von Keystone, E C

Volltext

B cells in rheumatoid arthritis: from hypothesis to the clinic von KEYSTONE, E. C

Volltext

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 von Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Emery, P, Keystone, E C, Schiff, M H, van Riel, P L C M, Weinblatt, M E, Weisman, M H

Volltext

Advances in targeted therapy: safety of biological agents von Keystone, E C

Volltext

Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis von Kuriya, B., Schieir, O., Valois, M. F., Pope, J. E., Boire, G., Bessette, L., Hazlewood, G., Thorne, J. C., Tin, D., Hitchon, C., Bartlett, S., Keystone, E. C., Bykerk, V. P., Barra, L.

Volltext

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of... von Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, J W J, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J

Volltext

Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibody von Isaacs, J. D., Cutolo, M., Keystone, E. C., Park, W., Braun, J.

Volltext

Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort von Ellingwood, L., Schieir, O., Valois, M. F., Bartlett, S. J., Bessette, L., Boire, G., Hazlewood, G., Hitchon, C., Keystone, E. C., Tin, D., Thorne, C., Bykerk, V. P., Pope, J. E., Baron, Murray, Bessette, Louis, Boire, Gilles, Bykerk, Vivian, Colmegna, Ines, Fallavollita, Sabrina, Haaland, Derek, Haraoui, Paul, Hazlewood, Glen, Hitchon, Carol, Jamal, Shahin, Joshi, Raman, Keystone, Ed, Nair, Bindu, Panopoulos, Peter, Pope, Janet, Rubin, Laurence, Thorne, Carter, Villeneuve, Edith, Zummer, Michel

Volltext

Health Assessment Questionnaire at One Year Predicts All‐Cause Mortality in Patients With Early Rheumatoid Arthritis von Fatima, Safoora, Schieir, O., Valois, M. F., Bartlett, S. J., Bessette, L., Boire, G., Hazlewood, G., Hitchon, C., Keystone, E. C., Tin, D., Thorne, C., Bykerk, V. P., Pope, J. E., Baron, Murray, Bessette, Louis, Boire, Gilles, Bykerk, Vivian, Colmegna, Ines, Fallavollita, Sabrina, Haaland, Derek, Haraoui, Paul, Hazlewood, Glen, Hitchon, Carol, Jamal, Shahin, Joshi, Raman, Keystone, Ed, Nair, Bindu, Panopoulos, Peter, Pope, Janet, Rubin, Laurence, Thorne, Carter, Villeneuve, Edith, Zummer, Michel

Volltext

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002) von Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Antoni, C E, Bijlsma, J W J, Burmester, G R, Cronstein, B, Keystone, E C, Kavanaugh, A, Klareskog, L

Volltext

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003) von Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Dougados, M, Emery, P, Gibofsky, A, Kavenaugh, A F, Keystone, E C, Klareskog, L, Russell, A S, van de Putte, L B A, Weisman, M H

Volltext

Developing an effective treatment algorithm for rheumatoid arthritis von Keystone, Edward C, Smolen, Josef, van Riel, Piet

Volltext

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management von Gardam, Michael A, Keystone, Edward C, Menzies, Richard, Manners, Steven, Skamene, Emil, Long, Richard, Vinh, Donald C

Volltext